Dabigatran-related serious medication errors: an analysis using data from VigiBase

[1] Holbrook A(2012)Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 e152S-e184

[2] Schulman S(2018)Identifying patient harm from direct oral anticoagulants Pa Patient Saf Advis 15 ---

[3] Witt DM(2016)DOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis Open Hear 3 1139-1151

[4] Valentine D(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 981-992

[5] Gaunt M(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 883-891

[6] Grissinger M(2011)Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2342-2352

[7] Hicks TSF(2009)Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 1287-1297

[8] Eisinga A(2012)Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 799-808

[9] Connolly SJ(2013)Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med 369 1115-1187

[10] Ezekowitz MD(2017)Post approval observational studies of non-vitamin K antagonist oral anticoagulants in atrial fibrillation JAMA 317 1175-4738

[1] Holbrook A(2012)Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 e152S-e184

[2] Schulman S(2018)Identifying patient harm from direct oral anticoagulants Pa Patient Saf Advis 15 ---

[3] Witt DM(2016)DOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis Open Hear 3 1139-1151

[4] Valentine D(2009)Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 981-992

[5] Gaunt M(2011)Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 883-891

[6] Grissinger M(2011)Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2342-2352

[7] Hicks TSF(2009)Dabigatran versus warfarin in the treatment of acute venous thromboembolism N Engl J Med 361 1287-1297

[8] Eisinga A(2012)Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N Engl J Med 366 799-808

[9] Connolly SJ(2013)Oral apixaban for the treatment of acute venous thromboembolism N Engl J Med 369 1115-1187

[10] Ezekowitz MD(2017)Post approval observational studies of non-vitamin K antagonist oral anticoagulants in atrial fibrillation JAMA 317 1175-4738